Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Takara Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Takara Bio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Rubicon Genomics Raises USD2 Million in Venture Financing 13
Partnerships 14
Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 14
Cellink Enters Research Agreement with Takara Bio Europe 15
Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 16
WaferGen Biosystems Enters into Agreement with Luxembourg Institute of Health 17
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 18
WaferGen Bio-systems Enters into Research Agreement with Genentech 19
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 20
Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 21
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 22
Licensing Agreements 23
Dong-A ST Enters into Licensing Agreement with Takara Bio 23
Takara Bio Enters into Licensing Agreement with Kyushu University 24
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 25
AmpliPhi Biosciences Enters into License Agreement with Takara Bio 26
Rubicon Genomics Enters into Licensing Agreement with SomaGenics 27
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 28
Takara Bio Enters into Licensing Agreement with ViaCyte 29
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 30
Takara Bio Expands Licensing Agreement With iPS Academia Japan 31
Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 32
WaferGen Biosystems Enters Into Licensing Agreement With Rutgers University For RNA Quality Control Technology 33
Equity Offering 34
WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 34
WaferGen Biosystems Raises USD20 Million in Public Offering of Units 35
WaferGen Biosystems Completes Second Tranche Of Private Placement Of Units For US$15 Million 37
Takara Bio Raises USD112 Million in Public Offering Of Common Stock 38
Acquisition 39
Takara Bio Acquires WaferGen Bio-Systems 39
Takara Bio Acquires Rubicon Genomics for USD75 Million 41
Takara Bio Acquires Cellectis, Biotech Company 42
Takara Bio Inc – Key Competitors 43
Takara Bio Inc – Key Employees 44
Takara Bio Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 46
Recent Developments 47
Strategy And Business Planning 47
Jan 30, 2018: Takara Bio: Regarding the establishment of research and manufacturing facilities for products such as regenerative medicine 47
Jan 30, 2018: Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products 48
Financial Announcements 49
Nov 28, 2017: Takara Bio: Consolidated Financial Statements for the Second Quarter Ended September 30, 2017 49
Product News 51
May 08, 2018: SMARTer ICELL8 technology aids in single-nuclei sequencing of triple-negative breast cancer to uncover chemoresistance evolution 51
01/17/2018: First Patient Enrolled into Phase I/II Clinical Trial of NY-ESO-1·siTCR Gene Therapy Against Synovial Sarcoma in Japan 52
Product Approvals 53
Mar 27, 2018: Announcement on product designation of NY-ESO-1·siTCR gene therapy product for synoviral sarcoma under “SAKIGAKE Designation System” by the Ministry of Health, Labour and Welfare 53
Jan 24, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1-siTCR gene therapy in Japan 54
Clinical Trials 55
Sep 27, 2017: First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan 55
Jun 01, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan 56
May 29, 2017: First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan 57
May 23, 2017: Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology 58
Jan 30, 2017: Takara Bio: Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan 59
Other Significant Developments 60
May 17, 2018: Takara Bio Announces Launch of Beta Cell Differentiation Service 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
Takara Bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Takara Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Takara Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Rubicon Genomics Raises USD2 Million in Venture Financing 13
Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 14
Cellink Enters Research Agreement with Takara Bio Europe 15
Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 16
WaferGen Biosystems Enters into Agreement with Luxembourg Institute of Health 17
Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 18
WaferGen Bio-systems Enters into Research Agreement with Genentech 19
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 20
Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 21
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 22
Dong-A ST Enters into Licensing Agreement with Takara Bio 23
Takara Bio Enters into Licensing Agreement with Kyushu University 24
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 25
AmpliPhi Biosciences Enters into License Agreement with Takara Bio 26
Rubicon Genomics Enters into Licensing Agreement with SomaGenics 27
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 28
Takara Bio Enters into Licensing Agreement with ViaCyte 29
Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 30
Takara Bio Expands Licensing Agreement With iPS Academia Japan 31
Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 32
WaferGen Biosystems Enters Into Licensing Agreement With Rutgers University For RNA Quality Control Technology 33
WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 34
WaferGen Biosystems Raises USD20 Million in Public Offering of Units 35
WaferGen Biosystems Completes Second Tranche Of Private Placement Of Units For US$15 Million 37
Takara Bio Raises USD112 Million in Public Offering Of Common Stock 38
Takara Bio Acquires WaferGen Bio-Systems 39
Takara Bio Acquires Rubicon Genomics for USD75 Million 41
Takara Bio Acquires Cellectis, Biotech Company 42
Takara Bio Inc, Key Competitors 43
Takara Bio Inc, Key Employees 44
Takara Bio Inc, Other Locations 45
Takara Bio Inc, Subsidiaries 45
Takara Bio Inc, Joint Venture 46
List of Figures
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10